Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee
1 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: kavsakp@mcmaster.ca.
2 National Heart Centre and Duke-National University of Singapore, Singapore, Singapore.
3 Department of Laboratory Medicine and Pathology, Hennepin Healthcare/HCMC, Minneapolis, Minnesota; USA and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
4 Department of Medical Biochemistry and Pharmacology and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway.
5 Emergency Department, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK; Healthcare Sciences Department, Manchester Metropolitan University, Manchester, UK.
6 Department of Clinical Chemistry and Transfusion Medicine, University of Gothenburg, Gothenburg, Sweden.
7 Department of Clinical Blood Sciences and Cardiology, St George's University Hospitals NHS Foundation Trust and St George's University of London, London, UK.
8 Servicio de Bioquímica Clínica, Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain; Departamento de Bioquímica y Biología Molecular, Universidad Autònoma de Barcelona, Barcelona, Spain.
9 Department of Cardiology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
10 Departments of Laboratory Medicine and Pathology and Cardiology, Mayo Clinic, Rochester, Minnesota.